Stelic Institute & Co..

tin4.jpg

July 19, 2016

  • Stelic announced that Phase 1 study has been accepted for publication in Journal of Crohn’s and Colitis, entitled "Phase 1 clinical study of siRNA targeting carbohydrate sulfotransferase 15 in Crohn’s disease patients with active mucosal lesions”.

July 14, 2016.

  • Stelic announced a new peer-reviewed publication describing the mechanism of CHST15 siRNA in mouse model of colitis, entitled “Pivotal role of carbohydrate sulfotransferese 15 in fibrosis and mucosal healing in mouse colitis” In PLoS One.

May 14, 2016.

  • Stelic announced that Dr. Arumugam at Niigata University of Pharmacy presented nonclinical results at Digestive Disease Week (DDW) SanDiego, US, entitled “Orally active siRNA targeting carbohydrate sulfotransferase 15 alleviates colonic mucosal injury in mice” as Lecture Presentation

May 14, 2016.

  • Stelic announced that Dr. Nishimura at Tokyo Metropolitan Geriatric Hospital presented interim results at Digestive Disease Week (DDW) Washington DC, US, entitled “An investigator-initiated trial of CHST15 dsRNA by EUS-FNI to investigate the safety and efficacy in patients with unresectable pancreatic cancer”.

ページの先頭へ